JP2020517678A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517678A5
JP2020517678A5 JP2019557789A JP2019557789A JP2020517678A5 JP 2020517678 A5 JP2020517678 A5 JP 2020517678A5 JP 2019557789 A JP2019557789 A JP 2019557789A JP 2019557789 A JP2019557789 A JP 2019557789A JP 2020517678 A5 JP2020517678 A5 JP 2020517678A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
group
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019557789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517678A (ja
JP6997800B2 (ja
Filing date
Publication date
Priority claimed from IL251949A external-priority patent/IL251949A0/en
Application filed filed Critical
Publication of JP2020517678A publication Critical patent/JP2020517678A/ja
Publication of JP2020517678A5 publication Critical patent/JP2020517678A5/ja
Application granted granted Critical
Publication of JP6997800B2 publication Critical patent/JP6997800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019557789A 2017-04-26 2018-04-26 神経炎症性障害の処置に使用される小有機分子 Active JP6997800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL251949 2017-04-26
IL251949A IL251949A0 (en) 2017-04-26 2017-04-26 Small organic molecules for use in the treatment of neuro-inflammatory diseases
PCT/IL2018/050463 WO2018198123A1 (en) 2017-04-26 2018-04-26 Small organic molecules for use in the treatment of neuroinflammatory disorders

Publications (3)

Publication Number Publication Date
JP2020517678A JP2020517678A (ja) 2020-06-18
JP2020517678A5 true JP2020517678A5 (enExample) 2021-04-01
JP6997800B2 JP6997800B2 (ja) 2022-02-04

Family

ID=62454780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557789A Active JP6997800B2 (ja) 2017-04-26 2018-04-26 神経炎症性障害の処置に使用される小有機分子

Country Status (9)

Country Link
US (2) US11103479B2 (enExample)
EP (1) EP3615022B1 (enExample)
JP (1) JP6997800B2 (enExample)
CN (1) CN110869015B (enExample)
AU (1) AU2018260535B2 (enExample)
CA (1) CA3061296A1 (enExample)
ES (1) ES2948767T3 (enExample)
IL (2) IL251949A0 (enExample)
WO (1) WO2018198123A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019122202A1 (en) * 2017-12-20 2019-06-27 Ecole Polytechnique Federale De Lausanne (Epfl) Sting inhibitors
CN112867489A (zh) * 2018-06-07 2021-05-28 达萨玛治疗公司 Sarm1抑制剂
CA3123215C (en) * 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY109202A (en) 1992-07-10 1996-12-31 Nihon Nohyaku Co Ltd Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
IT1313601B1 (it) 1999-08-05 2002-09-09 Isagro Ricerca Srl Fenilpirazoli ad attivita' erbicida
EP1088822A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
US6989451B2 (en) 2002-06-04 2006-01-24 Valeant Research & Development Heterocyclic compounds and uses thereof
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
GB0306357D0 (en) 2003-03-20 2003-04-23 Astrazeneca Ab Chemical compounds
EP1670425A4 (en) 2003-10-07 2008-04-16 Quark Pharmaceuticals Inc BONE MORPHOGENETIC PROTEIN (BMP) 2A AND ITS APPLICATIONS
US20060217390A1 (en) 2005-02-24 2006-09-28 Esmir Gunic Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CN100396667C (zh) * 2006-02-20 2008-06-25 中国医学科学院医药生物技术研究所 一组具有上调骨形成蛋白bmp-2表达活性的五元不饱和杂环化合物
AU2007288337B2 (en) 2006-08-21 2012-02-16 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
US8507501B2 (en) * 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
CA2805033A1 (en) * 2009-07-14 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Methods of increasing liver proliferation
AU2010282698A1 (en) 2009-08-11 2012-03-15 Allergan, Inc. Isothiozoles for treating conditions of the eye
JP5725469B2 (ja) * 2010-11-15 2015-05-27 学校法人北里研究所 骨分化阻害剤およびその製造方法
WO2013186777A2 (en) * 2012-06-14 2013-12-19 The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
US9682983B2 (en) * 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
EP3179857B1 (en) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life

Similar Documents

Publication Publication Date Title
JP2020507589A5 (enExample)
JP2012508252A5 (enExample)
JP2009538910A5 (enExample)
CN109328187A (zh) 一种具有fgfr抑制活性的新型化合物及其制备和应用
JP2015517574A5 (enExample)
JP2008505157A5 (enExample)
JP2010511721A5 (enExample)
JP2015535839A5 (enExample)
JP2020533352A5 (enExample)
JP2017519781A5 (enExample)
JP2009519243A5 (enExample)
JP2017533968A5 (enExample)
JP2005523922A5 (enExample)
JP2006505543A5 (enExample)
JP2005511699A5 (enExample)
JP2016505637A5 (enExample)
JP2020502047A5 (enExample)
JP2012513416A5 (enExample)
JP2016505614A5 (enExample)
JP2019535723A5 (enExample)
JP2020517678A5 (enExample)
JP2016507575A5 (enExample)
JP2013542267A5 (enExample)
JP2019527724A5 (enExample)
JP2015505301A5 (enExample)